Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
RNA interference (RNAi) is a collection of small RNA directed mechanisms that result in sequence specific inhibition of gene expression. The notion that RNAi could lead to a new class of therapeutics caught the attention of many investigators soon after its discovery. The field of applied RNAi therapeutics has moved very quickly from lab to bedside. The RNAi approach has been widely used for drug development and several phase I and II clinical trials are under way. However, there are still some concerns and challenges to overcome for therapeutic applications. These include the potential for off-target effects, triggering innate immune responses and most importantly obtaining specific delivery into the cytoplasm of target cells.
The RNAi for Therapeutic market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.
The report focuses on the RNAi for Therapeutic market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.
Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the RNAi for Therapeutic market.
Major Players in the RNAi for Therapeutic market are:
Alnylam Pharmaceuticals
AstraZeneca
Benitec Biopharma
Gradalis Incorporated
Ascletis Pharmaceuticals
Quark Pharmaceuticals
Tekmira Pharmaceuticals.
Silence Therapeutics
RXi Pharmaceuticals
Calando Pharmaceuticals
Astellas Pharma
Sylentis
Silenseed
BioSpring
CombiMatrix
GeneCopoeia
Celsion Corporation
Creative Animodel
Ensysce Biosciences
Celgene
Arrowhead Research
Roche Innovation Center Copenhagen (formerly Santaris Pharma)
Bayer Heathcare
Biogazelle
On the basis of types, the RNAi for Therapeutic market is primarily split into:
siRNA
miRNA
shRNA
On the basis of applications, the market covers:
Cancer
Cardiovascular
HBV
Others
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
2021
The RNAi for Therapeutic market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.
The report focuses on the RNAi for Therapeutic market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.
Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the RNAi for Therapeutic market.
Major Players in the RNAi for Therapeutic market are:
Alnylam Pharmaceuticals
AstraZeneca
Benitec Biopharma
Gradalis Incorporated
Ascletis Pharmaceuticals
Quark Pharmaceuticals
Tekmira Pharmaceuticals.
Silence Therapeutics
RXi Pharmaceuticals
Calando Pharmaceuticals
Astellas Pharma
Sylentis
Silenseed
BioSpring
CombiMatrix
GeneCopoeia
Celsion Corporation
Creative Animodel
Ensysce Biosciences
Celgene
Arrowhead Research
Roche Innovation Center Copenhagen (formerly Santaris Pharma)
Bayer Heathcare
Biogazelle
On the basis of types, the RNAi for Therapeutic market is primarily split into:
siRNA
miRNA
shRNA
On the basis of applications, the market covers:
Cancer
Cardiovascular
HBV
Others
Major Region
s or countries covered in this report:United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
Years considered for this report:
Historical Years:
2017-2021Base Year:
2021Estimated Year:
2022Forecast Period:
2022-2029Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
